Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Sponsor: EpiBiologics
Summary
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Official title: A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2026-04
Completion Date
2029-07
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
EPI-326
EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers. EPI-326 will be administered in the clinic via IV infusion.
Locations (5)
START Los Angeles
Los Angeles, California, United States
Astera Cancer Care
East Brunswick, New Jersey, United States
Sarah Cannon and HCA Research Institute
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States